Janssen Pharmaceutica Nv

Aragon Pharmaceuticals, Inc.

Astex Therapeutics Limited

Janssen Sciences Ireland Unlimited Company

Johan Erwin Edmond Weerts

Andras Horvath

Carina Leys

Cyril Ben Haim

Sigrid Carl Maria Stokbroekx

Tom Cornelis Hortense Govaerts

Jennifer Albaneze-Walker

Lieven Meerpoel

Patrick René Angibaud

Christopher Norbert Johnson

Christopher William Murray

Eddy Jean Edgard Freyne

Valerio Berdini

Gordon Saxty

Isabelle Noëlle Constance Pilatte

Werner Constant Johan Embrechts

Olivier Alexis Georges Querolle

Laurence Anne Mevellec

Jean Fernand Armand Lacrampe

David Charles Rees

Timothy Pietro Suren Perera

Gilbert Besong

Steven John Woodhead

Ronaldus Arnodus Hendrika Joseph Gilissen

Berthold Wroblowski

Pascal Ghislain André Bonnet

Christopher Charles Frederick Hamlett

Alexandra Papanikos

Elisabeth Thérèse Jeanne Pasquier

Rhalid Akkari

Michael Reader

Gregor James MacDonald

Michiel Luc Maria Van Gool

José Manuel Bartolomé-Nebreda

Susana Conde-Ceide

Óscar Delgado-González

María Luz Martín-Martín

Sergio-Alvar Alonso-de Diego

Yolande Lydia Lang

Greta Constantia Peter Vanhoof

Bart Petrus Anna Maria Jozef Medaer

Stijn Wuyts

Joaquin Pastor-Fernández

Joannes Josephus Maria Willems

Kelly Ann Swinney

Julius W J Dickens

Ioannes Nicolaos Houpis

Julius Walter Jozef Dickens

Yves Georges Ruysschaert

Gilbert Ebai Besong

Zhihui Lu

Hongyu Tan

Licheng Han

Marcello Rasparini

Corina Mathilde Jansen

ÓScar Delgado-GONZÁLEZ

Julius WJ Dickens

Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer. 

Process for the preparation of a diarylthiohydantoin compound

Processes for the preparation of a diarylthiohydantoin compound

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pyrazolyl quinoxaline kinase inhibitors

This invention provides novel crystalline forms of mono-HCl salts and a mono-HCl salt hydrate of JNJ-26481585, an inhibitor of histone deacetylases. The invention also relates to processes for production of these forms, to intermediates used in these processes, to pharmaceutical compositions comprising these forms, and to the use of these forms in medical treatment for instance as a medicine to inhibit proliferative conditions, such as cancer and leukemia.

Mono-hydrochloric salts of an inhibitor of histone deacetylase

The present invention relates to novel imidazo[1,2-]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors

The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound.

Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline

The object of the present invention is a novel mandelate salt of a substituted tetracyclic tetrahydrofuran derivative according to Formula (I) the N-oxide forms and the stereochemically isomeric forms thereof, wherein Rand Reach independently are hydrogen or Calkyl and Rand Reach independently are hydrogen or halogen. In the foregoing definitions Calkyl defines straight and branched saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl or hexyl. The novel mandelate salt is not light-sensitive and is far more stable than the prior art salts at room temperature, enhanced temperature and at relative high humidities and in aqueous media. Also disclosed are pharmaceutical compositions comprising mandelate salts according to the invention, mandelate salts according to the invention for use as a medicine, a process for preparing the mandelate salts according to the invention and the use of the mandelate salts and pharmaceutical compositions comprising mandelate salts according to the invention for the treatment or the prevention of CNS disorders, cardiovascular disorders and gastrointestinal disorders.

Mandelates salts of substituted tetracyclic tetrahydrofuran derivatives

Growing community of inventors

Beerse, Belgium

Johan Erwin Edmond Weerts